• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Plaintiffs to J&J on fraud claims: Prove it

Plaintiffs to J&J on fraud claims: Prove it

January 29, 2015 By Brad Perriello

Plaintiffs to J&J on fraud claims: Prove it

Allegations made by Johnson & Johnson (NYSE:JNJ) about a campaign of telephone solicitation aimed at generating more lawsuits over its pelvic mesh products aren’t backed by any proof, the plaintiffs argued last week, saying the company’s move to force the plaintiffs to prove they have valid claims is just a delaying tactic.

The company wants Judge Joseph Goodwin, who’s overseeing the multi-district litigation that covers 10s of thousands of product liability lawsuits, to force plaintiffs to prove that they have a legitimate claim, according to court documents. And it wants Goodwin to force the plaintiffs’ lawyers to testify under oath and in front of the judge "to determine who may be profiting from the unethical and illegal direct solicitation of women and whether further investigation of others is warranted," according to the documents.

The plaintiffs countered that there’s no proof that any of the lawsuits against Johnson & Johnson are fraudulent.

"Defendants have failed to establish that a single complaint out of 23,000-plus Ethicon cases is fraudulent. Not one. Indeed, independent random sampling – a survey governed by a protocol defendants developed – failed to reveal fraud in any filings," the plaintiffs claimed in a court filing. "Notwithstanding such clear evidence, defendants inferentially leap from citing the unscrupulous acts of a call center which, by defendants’ own admission, is likely unaffiliated with any of the plaintiff lawyers before this court, to the shocking claim that fraudulent filings are pervasive."

"Stripped of its anecdotal histrionics, defendants’ motion lacks any substance at all," according to the filing. "The absence of any established link between the call center’s actions and any plaintiff in this litigation means there is no basis for imposing any new discovery obligations on individual plaintiffs (much less on their lawyers)."

Johnson & Johnson’s Ethicon and Mentor subsidiaries aren’t the only medical device companies facing personal injury lawsuits over thier pelvic mesh offerings. C.R. Bard (NYSE:BCR), Boston Scientific (NYSE:BSX) and others are each facing thousands of the suits; those that have made it to trial have largely gone the plaintiffs’ way.

Last weekJ&J agreed to settle another batch of cases filed against Mentor. In November 2014, a jury in West Virginia awarded 4 women $18.5 million for injuries they said were caused by Boston Scientific‘s (NYSE:BSX) Obtryx device for stress urinary incontinence, including $4 million for "gross negligence." That verdict came a week after a Miami jury awarded $26.7 million to 4 women implanted with the company’s Pinnacle device for pelvic organ prolapse.

Bard, whichearlier this month lost a bid to delay some of its trials, last October inked a settlement deal for some 500 of the cases that’s reportedly worth about $21 million.

Filed Under: Legal News, News Well, Product Liability Tagged With: Johnson and Johnson, Pelvic Mesh Lawsuits

More recent news

  • Ambu wins FDA clearance for first single-use cysto-nephroscope
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy